The FDA accepted for priority review the supplemental Biologics License Application for PD-1 inhibitor Libtayo (cemiplimab-rwlc), a monoclonal antibody, to treat patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
